Background: The standard treatment of type II diabetes mellitus (T2DM) more often explicitly decreased efficacy resulting in improper glycemic control. Hence, there is a need for alternative therapy like Gliptins, which play a key role in the management of diabetes mellitus. The current research studies the prescription pattern analysis of Teneligliptin in the therapy of T2DM patients. Materials and Methods: The investigation was a prospective observational study with a sample size of 302 cases in a diabetic centre in Erode, India. The patients were prescribed Teneligliptin along with Insulin and other oral antidiabetic drugs (OAD) and drugs for other co-morbid conditions. Patient details were collected in connection to prescribed medicines, biochemical lab data, other co-morbid conditions, and complications related to T2DM. Results: The prescription patterns of about 302 patients with T2DM, initially prescribed with gliptin, were reviewed. Teneligliptin was the gliptin drug prescribed along with insulin and other OADs. The commonly prescribed regimen was a combination of Teneligliptin, Metformin and Glibenclamide. Out of 302 patients, 169 were men and 133 were women within the age category of 50-59 years. The result of this study shows that the duration of diabetes and gender was statistically significant with p-value < 0.003 and 0.01 respectively. Conclusion: The analysis disclosed that the most repeatedly prescribed DPP4 inhibitor is Teneligliptin, mostly prescribed as an add-on therapy with metformin, insulin and other OAD drugs. Also, the current drug treatment and the planning of multiple drug interventions with changes in lifestyle for T2DM are much needed.